Bristol Myers Squibb (BMY) Competitors

Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Is AMGN or BMY a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.2%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 92.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media favor AMGN or BMY?

In the previous week, Amgen had 9 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 50 mentions for Amgen and 41 mentions for Bristol Myers Squibb. Amgen's average media sentiment score of 1.15 beat Bristol Myers Squibb's score of 1.11 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	45 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	32 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AMGN or BMY more profitable?

Amgen has a net margin of 17.39% compared to Bristol Myers Squibb's net margin of 11.38%. Amgen's return on equity of 176.11% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	17.39%	176.11%	12.39%
Bristol Myers Squibb	11.38%	87.62%	15.98%

Do analysts rate AMGN or BMY?

Amgen currently has a consensus target price of $307.82, indicating a potential upside of 3.63%. Bristol Myers Squibb has a consensus target price of $58.00, indicating a potential upside of 21.97%. Given Bristol Myers Squibb's higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35
Bristol Myers Squibb	2 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.32

Which has more volatility & risk, AMGN or BMY?

Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in AMGN or BMY?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable valuation & earnings, AMGN or BMY?

Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.78	$4.09B	$10.96	27.10
Bristol Myers Squibb	$47.64B	2.03	-$8.95B	$2.67	17.81

Summary

Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.